Home › NCT05822427

Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Receipt of at least 1 dose of azer-cel in an Imugene clinical study.
* A signed informed consent form (ICF).
* Willingness and ability to adhere to the study schedule and all other protocol requirements.

Exclusion Criteria:

* No unique exclusion criteria apply to this study.

About the study

The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in an Imugene Clinical Study. The main questions it aims to answer are:

* What are the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)? * What is the duration of response and overall survival time after taking an allogeneic CAR T-Cell product on an Imugene clinical study?

Participants will have a yearly visit either face to face or remotely for up to 15 years to check for CEI.

Sponsor: Imugene Limited · Participants: 75 · Started: Aug 25, 2020

Contact the study team

• Clinical Imugene Limited · Phone: 1 984 245 0082

Official record on ClinicalTrials.gov — NCT05822427

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.